Allogene Therapeutics shares surged over 50% to $4.32 after data from the planned interim futility analysis of its pivotal Phase 2 ALPHA3 trial in first-line consolidation large B-cell lymphoma. The update appears to have materially improved investor confidence in the program's prospects. The move is significant for the stock, though the broader market impact is limited to the biotech space.
Allogene Therapeutics shares surged over 50% to $4.32 after data from the planned interim futility analysis of its pivotal Phase 2 ALPHA3 trial in first-line consolidation large B-cell lymphoma. The update appears to have materially improved investor confidence in the program's prospects. The move is significant for the stock, though the broader market impact is limited to the biotech space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
